EUVIMEDEUVIMED entdecken
Multizentrische Studie

Prognostic Value of 18 F-FDG PET/CT Assessment After Radiotherapy of Squamous Cell Carcinoma of the Anus in Patients from the National Multicentric Cohort FFCD-ANABASE

Virginie Combet-Curt, Chloé Buchalet, Karine Le Malicot, Claire Lemanski, Emmanuel Deshayes, Nathalie Bonichon-Lamichhane, Astrid Lièvre, Florence Huguet, Ghoufrane Tlili, Véronique Vendrely

Journal of Nuclear Medicine · 2024

DOI: 10.2967/jnumed.124.267626 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Nuclear Medicine, 2024. Verfasst von Virginie Combet-Curt und 9 weiteren Autor:innen. Beteiligte Einrichtung: Radiotherapy, CHU Bordeaux, Bordeaux, France; virginie.combet-curt@chu-bordeaux.fr. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Anus Neoplasms, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to evaluate the prognostic value of 18F-FDG PET/CT qualitative assessment in terms of recurrence-free survival (RFS), colostomy-free survival (CFS), and overall survival (OS) after radiation therapy (RT) of squamous cell carcinoma of the anus (SCCA). Secondary objectives were to evaluate the prognostic value of baseline and posttherapeutic quantitative 18F-FDG PET/CT parameters in terms of RFS, CFS, and OS.

Methods

We included all consecutive patients from the French multicentric cohort FFCD-ANABASE who had undergone 18F-FDG PET/CT at baseline and 4-6 mo after RT or chemoradiotherapy for a localized SCCA. Qualitative assessments separated patients with complete metabolic response (CMR) and non-CMR. Quantitative parameters were measured on baseline and posttreatment 18F-FDG PET/CT. RFS, CFS, and OS were analyzed using the Kaplan-Meier method. Associations among qualitative assessments, quantitative parameters, and RFS, CFS, and OS were analyzed using univariate and multivariate Cox regression.

Results

Among 1,015 patients treated between January 2015 and April 2020, 388 patients (300 women and 88 men) from 36 centers had undergone 18F-FDG PET/CT at diagnosis and after treatment. The median age was 65 y (range, 32-90 y); 147 patients (37.9%) had an early-stage tumor and 241 patients (62.1%) had a locally advanced-stage tumor; 59 patients (15.2%) received RT, and 329 (84.8%) received chemoradiotherapy. The median follow-up was 35.5 mo (95% CI, 32.8-36.6 mo). Patients with CMR had better 3-y RFS, CFS, and OS, at 84.2% (95% CI, 77.8%-88.9%), 84.7% (95% CI, 77.2%-89.3%), and 88.6% (95% CI, 82.5%-92.7%), respectively, than did non-CMR patients, at 42.1% (95% CI, 33.4%-50.6%), 47.9% (95% CI, 38.1%-56.8%), and 63.5 (95% CI, 53.2%-72.1%), respectively (P < 0.0001). Quantitative parameters were available for 154 patients from 3 centers. The following parameters were statistically significantly associated with 3-y RFS: baseline SUVmax (primitive tumor [T]) (hazard ratio [HR], 1.05 [95% CI, 1.01-1.1; P = 0.018]), SUVpeak (T) (HR, 1.09 [95% CI, 1.02-1.15; P = 0.007]), MTV 41% (T) (HR, 1.02 [95% CI, 1-1.03; P = 0.023]), MTV 41% (lymph node [N]) (HR, 1.06 [95% CI, 1.03-1.1; P < 0.001]), MTV 41% (T + N) (HR, 1.02 [95% CI, 1-1.03; P = 0.005]), and posttreatment SUVmax (HR, 1.21 [95% CI, 1.09-1.34; P < 0.001]).

Conclusion

Treatment response assessed by 18F-FDG PET/CT after RT for SCCA has a significant prognostic value.18F-FDG PET/CT could be useful for adapting follow-up, especially for patients with locally advanced-stage tumors. Quantitative parameters could permit identification of patients with a worse prognosis but should be evaluated in further trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyFluorodeoxyglucose F18Anus NeoplasmsCarcinoma, Squamous CellHumansMaleFemaleAgedMiddle AgedPrognosisCohort StudiesAged, 80 and overAdult

Stichwörter der Autor:innen

18F-FDG PET/CTPETanal cancerchemoradiotherapysquamous cell carcinoma of the anus

Substanzen

Fluorodeoxyglucose F18

Autor:innen und Institutionen

  • Radiotherapy, CHU Bordeaux, Bordeaux, France; virginie.combet-curt@chu-bordeaux.fr.
  • Radiotherapy, ICM-Montpellier, Montpellier, France.
  • Biostatistics, University of Burgundy, FFCD, Dijon, France.
  • Nuclear Medicine, ICM-Montpellier, Montpellier, France.
  • Radiotherapy, Clinique Bordeaux Tivoli-Ducos, Bordeaux, France.
  • Hepatogastroenterology Department, CHU Rennes, Rennes, France.

Zitieren

APA

Combet-Curt, V., Buchalet, C., Le Malicot, K., Lemanski, C., Deshayes, E., Bonichon-Lamichhane, N., Lièvre, A., Huguet, F., Tlili, G., & Vendrely, V. (2024). Prognostic Value of 18 F-FDG PET/CT Assessment After Radiotherapy of Squamous Cell Carcinoma of the Anus in Patients from the National Multicentric Cohort FFCD-ANABASE. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.124.267626

Vancouver

Combet-Curt V, Buchalet C, Le Malicot K, Lemanski C, Deshayes E, Bonichon-Lamichhane N, et al. Prognostic Value of 18 F-FDG PET/CT Assessment After Radiotherapy of Squamous Cell Carcinoma of the Anus in Patients from the National Multicentric Cohort FFCD-ANABASE. Journal of Nuclear Medicine. 2024. doi:10.2967/jnumed.124.267626

BibTeX
@article{CombetCurt2024,
  author = {Combet-Curt, Virginie and Buchalet, Chloé and Le Malicot, Karine and Lemanski, Claire and Deshayes, Emmanuel and Bonichon-Lamichhane, Nathalie and Lièvre, Astrid and Huguet, Florence and Tlili, Ghoufrane and Vendrely, Véronique},
  title = {Prognostic Value of 18 F-FDG PET/CT Assessment After Radiotherapy of Squamous Cell Carcinoma of the Anus in Patients from the National Multicentric Cohort FFCD-ANABASE},
  journal = {Journal of Nuclear Medicine},
  year = {2024},
  doi = {10.2967/jnumed.124.267626}
}
Kostenlos starten →